

suggests that MTT offers a safe and effective means for alleviating biochemical deficit(s) inherent in muscles of DMD.

Supported by grants from a private foundation, the Muscular Dystrophy Association, Sandoz Pharmaceutical Co, and Walgreens to P. K. L. Q. F. is a fellow of the Boehringer Ingelheim Fonds Foundation. We thank Dr William Warner for surgical assistance and Dr Rao Paidipalli for the anaesthesia; Dr Nigel Cooper provided fluorescent microscopy. We acknowledge use of facilities in the University of Tennessee Memphis Clinical Research Center and in the Le Bonheur Children's Medical Center. Dystrophin antibodies were provided by Prof Eric Hoffman, Prof Hideo Sugita, and Genica Pharmaceuticals Corporation.

Departments of Neurology
and Pediatrics,
University of Tennessee Memphis,
Memphis, Tennessee 38163, USA

PETER K. LAW
TULIO E. BERTORINI
TENA G. GOODWIN
MING CHEN
QIUWEN FANG
HUA-JU LI
DANA S. KIRBY
J. ANN FLORENDO
HENRY G. HERROD
GERALD S. GOLDEN

1. Law PK, Goodwin TG, Wang MG. Normal myoblast injections provide genetic treatment for murine dystrophy. *Muscle Nerve* 1988; **11**: 525-33.
2. Law PK, Goodwin TG, Li HJ. Histoincompatible myoblast injection improves muscle structure and function of dystrophic mice. *Transplant Proc* 1988; **20**: 1114-19.
3. Law PK, et al. Pathogenesis and treatment of hereditary muscular dystrophy. In: Kakulas B, Mastaglia F eds. Pathogenesis and therapy of Duchenne and Becker muscular dystrophy. New York: Raven Press, 1990: 101-08.
4. Partridge TA, Morgan JE, Coulton GR, et al. Conversion of *mdx* myofibres from dystrophin-negative to positive by injection of normal myoblasts. *Nature* 1989; **33**: 176-79.
5. Bonilla E, Samitt CE, Miranda AF, et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. *Cell* 1988; **54**: 447-52.
6. Patel K, Dunn MJ, Strong PN, Dubowitz V. Dystrophin and nebulin in the muscular dystrophies. *J Neural Sci* 1988; **87**: 315-26.